


## Supporting Information


# An Integrated Pan-Cancer Analysis and Structure-Based Virtual Screening of GPR15

Yanjing Wang <sup>1,†</sup>, Xiangeng Wang <sup>1,†</sup>, Yi Xiong <sup>1</sup>, Cheng-Dong Li <sup>1</sup>, Qin Xu <sup>1</sup>, Lu Shen <sup>2</sup>, Aman Chandra Kaushik <sup>4,\*</sup> and Dong-Qing Wei <sup>1,3,\*</sup>


- <sup>1</sup> State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, and Joint Laboratory of International Cooperation in Metabolic and Developmental Sciences, Ministry of Education, Shanghai Jiao Tong University, Shanghai 200240, China; [wangyanjing@sjtu.edu.cn](mailto:wangyanjing@sjtu.edu.cn) (Y.W.); [wangxiangeng@sjtu.edu.cn](mailto:wangxiangeng@sjtu.edu.cn) (X.W.); [xiongyi@sjtu.edu.cn](mailto:xiongyi@sjtu.edu.cn) (Y.X.); [lcd805728463@sjtu.edu.cn](mailto:lcd805728463@sjtu.edu.cn) (C.-D.L.); [xuqin523@foxmail.com](mailto:xuqin523@foxmail.com) (Q.X.)
  - <sup>2</sup> Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai 200030, China; [yoyomailer@sjtu.edu.cn](mailto:yoyomailer@sjtu.edu.cn) (L.S.)
  - <sup>3</sup> Peng Cheng Laboratory, Vanke Cloud City Phase I Building 8, Xili Street, Nanshan District, Shenzhen 518055, China
  - <sup>4</sup> Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China
- \* Correspondence: [dqwei@sjtu.edu.cn](mailto:dqwei@sjtu.edu.cn) (D.-Q.W.); [amanbioinfo@sjtu.edu.cn](mailto:amanbioinfo@sjtu.edu.cn) (A. C.K.)
- † These authors contributed equally to this work.




**Figure 1.** Differential of GPR15 between tumor and normal in COAD and READ.



**Figure 2.** Mutational landscape of COAD and READ. A. Waterfall plot of the mutations among 399 COAD patients. B. Waterfall plot of the mutations among 137 READ patients. Top 20 frequently mutated genes are listed. .



**Figure 3.** Mutational pattern of GPR15 in 5 cancers. Lollipop plot that depicts the mutational distribution and protein domains for GPR15 in five different cancers with labelled hotspots.



**Figure 4.** Heat maps for top 200 genes with altered expression between the GPR15 high expression and *GPR15* low expression groups.



```

          α6                                     α7
          1 10 20 30 40 50 60
4YAY  N I I F V M I P T L V S I I F V V G F G N S L V V I V I V F Y M K L R T V A S V F L L N L A A D L C F L P L P L W
GPCR15 P M T S V F L P V F V T A V F L T G V L G N I V L M G A L H K P G S R R L T D H F I I N L A A S D F I P L V D L P L W


          α8
          70 80 90 100 110 120
4YAY  A V Y T A M E Y R P P F G N Y L C K I A S A S V S N L V A S V F L L C L S I D R Y L A I V P M S P H R T M L V
GPCR15 V D K B A S L G R W R T G S F L C K G S S Y M I S V N M H C S V L L L T C M S V D R Y L A I V P V V S R K F R T D C

          α9      α10  β1      β2      α11
          130 140 150 160 170 180
4YAY  A R V V C T I I T L A G A S D A I I H R N V F F E N I N I T V C A R A Y S Q N S T I I G L G F T K N L G F
GPCR15 A R V V C A S T I P I S C L G L P L L G R L L G R L I L I D K . . . . P Y C A R K K A T F I R L I W S V A L F T F


          α12                                     α13
          190 200 210 220 230
4YAY  L F P E I L L S V T L W K A I K K A Y E I Q K N K P R N D D I F K T I V A I V D F P F S W P H Q F P F L D
GPCR15 F V P L S L V P C C L A R K L C A R L Q S G K H N K L K K S I K I I F V V A A L V S W P F N F R P L A

          α14      α15  η1      α16
          240 250 260 270 280 290
4YAY  V L I Q G I I R D C R I A D V D T A M P I T I C I A Y F N N C D N F L F Y G F L G K K F K R Y F T O L D . .
GPCR15 V L S C L R Q E H Y L P S A H P Q L G M P V S G P L A P A N S C V N F F I Y I F D S Y I R R A I V H C L C P


```



**Figure 6.** Sequence alignment of the template sequence with the target sequence. The right figure shows the superimposed structure of the homology modeling of GPR15 protein (purple) and template protein (light blue) along with the alignment.




**Figure 7.** The structure of top 8 hits selected from virtual screening.



**Figure 8.** The 2D protein-ligand interactions of representative docking pose of the top five compounds complexed with the GPR15 protein. Hydrogen bonds are illustrated by purple lines, and Pi-pi interactions are marked by green lines.





**Figure 9.** The salt-bridge distance between C5:N1 and Lys261:NZ during 100 ns simulations.

**Table 1.** Top 5 pathways of genes in integrated network.

Pathway identifier	Pathway name	#Entities found	#Entities total	Entities ratio	Entities pValue	Entities FDR	#Reactions found	#Reactions total	Reactions ratio	Submitted entities found
R-HSA-450385	Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA	2	19	0.00 1351 45	0.002 31538	0.24 3115 35	3	6	5.01 $\times 10^{-4}$	YWHAB;E XOSC1
R-HSA-450513	Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA	2	19	0.00 1351 45	0.002 31538	0.24 3115 35	2	4	3.34 $\times 10^{-4}$	YWHAB;E XOSC1
R-HSA-525793	Myogenesis	2	32	0.00 2276 12	0.006 36962	0.27 0461 84	3	14	0.001 1682 24	MYF6 ;MEF2 D
R-HSA-375170	CDO in myogenesis	2	32	0.00 2276 12	0.006 36962	0.27 0461 84	3	14	0.001 1682 24	MYF6 ;MEF2 D
R-HSA-388396	GPCR downstream signalling	11	1355	0.09 6379 54	0.009 67472	0.27 0461 84	21	253	0.021 1114 82	Submitted entities found

**Table 2.** Top 10 potential cancer types whose prognosis is associated with GPR15. "Rank" stands for the expression abundance rank among all genes.

Cancer	Cox Coefficient	P-Value	FDR Corrected	Rank	Median Expression	Mean Expression
STAD	-0.27	$2.20 \times 10^{-3}$	$1.35 \times 10^{-1}$	269	3.95	15.47
HNSC	-0.205	$6.40 \times 10^{-3}$	$1.50 \times 10^{-1}$	707	6.15	20.99
LUAD	-0.161	$3.90 \times 10^{-2}$	$1.75 \times 10^{-1}$	3711	5.66	15.34
COAD	-0.159	$1.50 \times 10^{-1}$	$5.58 \times 10^{-1}$	4299	4.22	15.93
READ	-0.328	$1.60 \times 10^{-1}$	$9.39 \times 10^{-1}$	2696	6.83	16.1
LUSC	0.07	$3.30 \times 10^{-1}$	$7.93 \times 10^{-1}$	6956	6.93	23.8

KIRC	-0.059	$4.80 \times 10^{-1}$	$6.06 \times 10^{-1}$	13174	1.66	7.49
LAML	0.078	$5.10 \times 10^{-1}$	$8.11 \times 10^{-1}$	9516	4.88	11.36
ESCA	0.021	$8.80 \times 10^{-1}$	$9.91 \times 10^{-1}$	14833	3.06	13.77

**Table S3.** Correlations between immune infiltrating cells and GPR15 expression level

Cancer	Cell types	Correlation coefficient	P-value	Statistic difference	Correlation strength
COAD	Purity	-0.18383902	$1.92 \times 10^{-4}$	YES	Very weak
	B Cell	0.280950455	$9.16 \times 10^{-9}$	YES	Weak
	CD8+ T cell	0.010383547	$8.35 \times 10^{-1}$	NO	Very weak
	CD4+ T cell	0.292130319	$2.38 \times 10^{-9}$	YES	Weak
	Macrophage	0.001880939	$9.69 \times 10^{-1}$	NO	Very weak
	Neutrophil	0.101341327	$4.25 \times 10^{-2}$	YES	Very weak
	Dendritic Cell	0.149759501	$2.61 \times 10^{-3}$	YES	Very weak
HNSC	Purity	-0.245063398	$3.55 \times 10^{-8}$	YES	Weak
	B Cell	0.342491455	$1.51 \times 10^{-14}$	YES	Weak
	CD8+ T cell	0.394605334	$4.12 \times 10^{-19}$	YES	Weak
	CD4+ T cell	0.318984967	$8.17 \times 10^{-13}$	YES	Weak
	Macrophage	0.214987783	$1.86 \times 10^{-6}$	YES	Weak
	Neutrophil	0.2472179	$4.21 \times 10^{-8}$	YES	Weak
	Dendritic Cell	0.315589752	$1.32 \times 10^{-12}$	YES	Weak
LUAD	Purity	-0.314118069	$8.96 \times 10^{-13}$	YES	Weak
	B Cell	0.247881511	$3.28 \times 10^{-8}$	YES	Weak
	CD8+ T cell	0.259140634	$6.50 \times 10^{-9}$	YES	Weak
	CD4+ T cell	0.088275201	$5.22 \times 10^{-2}$	NO	Very weak
	Macrophage	-0.022504199	$6.21 \times 10^{-1}$	NO	Very weak
	Neutrophil	0.174530359	$1.15 \times 10^{-4}$	YES	Very weak
	Dendritic Cell	0.079029988	$8.11 \times 10^{-2}$	NO	Very weak
STAD	Purity	-0.132792751	$9.55 \times 10^{-3}$	YES	Very weak
	B Cell	0.24206621	$2.55 \times 10^{-6}$	YES	Weak
	CD8+ T cell	0.306357949	$1.76 \times 10^{-9}$	YES	Weak
	CD4+ T cell	0.328503282	$1.17 \times 10^{-10}$	YES	Weak
	Macrophage	0.224593775	$1.29 \times 10^{-5}$	YES	Weak
	Neutrophil	0.257657293	$4.87 \times 10^{-7}$	YES	Weak
	Dendritic Cell	0.284949911	$2.32 \times 10^{-8}$	YES	Weak

**Table 4.** The binding free energy ( $\Delta G_{bind}$  in kcal mol<sup>-1</sup>) and different energy components for the compound-GPR15 complexes, such as electrostatic energy ( $\Delta G_{ele}$ ), van der Waals ( $\Delta G_{vdW}$ ), and solvation energy ( $\Delta G_{SA}$  and  $\Delta G_{polar}$ ).

No.	$\Delta G_{bind}$	$\Delta G_{vdw}$	$\Delta G_{ele}$	$\Delta G_{PA}$	$\Delta G_{SA}$
C1	$-36.16 \pm 0.68$	$-56.58 \pm 0.66$	$-0.54 \pm 0.20$	$27.87 \pm 0.65$	$-6.90 \pm 0.06$
C2	$-47.64 \pm 0.38$	$-87.90 \pm 0.32$	$-7.79 \pm 0.21$	$57.96 \pm 0.42$	$-9.90 \pm 0.02$
C3	$-36.51 \pm 0.39$	$-71.81 \pm 0.40$	$-11.21 \pm 0.30$	$54.94 \pm 0.45$	$-8.45 \pm 0.02$
C4	$-33.67 \pm 0.32$	$-52.21 \pm 0.35$	$-13.35 \pm 0.26$	$37.15 \pm 0.36$	$-5.25 \pm 0.02$
C5	$-38.88 \pm 0.35$	$-73.81 \pm 0.33$	$-10.39 \pm 0.21$	$53.72 \pm 0.31$	$-8.3 \pm 0.03$
C6	$-23.49 \pm 0.35$	$-40.75 \pm 0.30$	$-5.03 \pm 0.36$	$27.56 \pm 0.40$	$-5.29 \pm 0.02$
C7	$-26.76 \pm 0.38$	$-44.73 \pm 0.27$	$-5.63 \pm 0.14$	$28.67 \pm 0.26$	$-5.04 \pm 0.01$
C8	$-18.52 \pm 0.38$	$-47.79 \pm 0.24$	$-8.51 \pm 0.26$	$43.46 \pm 0.33$	$-5.68 \pm 0.01$

**Table 5.** Simulation conditions for all systems.

<b>No.</b>	<b>System</b>	<b>Time (ns)</b>	<b>POPC</b>	<b>Ions</b>	<b>Water</b>
1	C1	100	149	24Na <sup>+</sup> , 39Cl <sup>-</sup>	9277
2	C2	100	149	23Na <sup>+</sup> , 38Cl <sup>-</sup>	9293
3	C3	100	149	23Na <sup>+</sup> , 38Cl <sup>-</sup>	9254
4	C4	100	150	24Na <sup>+</sup> , 39 Cl <sup>-</sup>	9276
5	C5	100	150	24Na <sup>+</sup> , 39Cl <sup>-</sup>	9306
6	C6	100	149	24Na <sup>+</sup> , 39Cl <sup>-</sup>	9259
7	C7	100	150	24Na <sup>+</sup> , 39Cl <sup>-</sup>	9290
8	C8	100	150	24Na <sup>+</sup> , 39Cl <sup>-</sup>	9263